Jensen Lars H, Danenberg Kathleen D, Danenberg Peter V, Jakobsen Anders
Department of Oncology, Danish Colorectal Cancer Group South, University of Southern Denmark, Vejle Hospital, Denmark.
Clin Colorectal Cancer. 2007 Mar;6(6):433-5. doi: 10.3816/CCC.2007.n.012.
The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine.
Microdissection of paraffin-embedded tumor tissue, RNA extraction, and quantitative polymerase chain reaction were performed on tumors obtained from 37 patients with advanced CRC.
The median relative gene expression of MSH2 was 0.65 (quartiles 0.5-0.8) in nonresponders and 1.25 (quartiles 0.92-1.38) for responders (P = 0.038). High expression of MSH2 was associated with a hazard ratio of 0.5 (95% confidence interval, 0.23-1.11; P = 0.083) in survival analysis.
The higher gene expression of MSH2 in responders and the trend for predicting overall survival indicates a predictive value of this marker in the treatment of advanced CRC with capecitabine.
本研究的目的是评估DNA错配修复基因MSH2的基因表达，作为一线卡培他滨治疗晚期结直肠癌（CRC）的预测标志物。
对37例晚期CRC患者的肿瘤进行石蜡包埋肿瘤组织的显微切割、RNA提取和定量聚合酶链反应。
无反应者中MSH2的中位相对基因表达为0.65（四分位数0.5 - 0.8），有反应者为1.25（四分位数0.92 - 1.38）（P = 0.038）。在生存分析中，MSH2的高表达与风险比0.5相关（95%置信区间，0.23 - 1.11；P = 0.083）。
有反应者中MSH2的基因表达较高，且有预测总生存的趋势，表明该标志物在卡培他滨治疗晚期CRC中有预测价值。
